Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…

ESMO Open. 2017 Mar 27;2(1):e000162. doi: 10.1136/esmoopen-2017-000162. eCollection 2017.

Satheesh Thungappa¹, Jose Ferri^{1

2}, Christian Caglevic³, Francesco Passiglia^{1

4}, Luis Raez⁵, Christian Rolfo^{1

6}

¹ Phase I Early Clinical Trials Unit, Department of Oncology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium.
² Consorci Hospital General Universitari de Valencia, Valencia, Comunitat Valenciana, Spain.
³ Early Development Drugs Unit, Medical Oncology Department, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile.
⁴ Department of Oncology, Universita degli Studi di Palermo, Palermo, Sicilia, Italy.
⁵ Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Pembroke Pines, Florida, USA.
⁶ Center for Oncological Research (CORE), Antwerp University, Wilrijk, Belgium.

No abstract available

Keywords: Immune checkpoints; NSCLC; PDL-1/PD-1.

Publication types